Search
Research
COVID-19-Related Submission Priorities From the Journal of the Pediatric Infectious Diseases SocietyChristopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
Research
Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptorsPre-existing pathogen-specific memory T cell responses can contribute to multiple adverse outcomes including autoimmunity and drug hypersensitivity. How the specificity of the T cell receptor (TCR) is subverted or seconded in many of these diseases remains unclear. Here, we apply abacavir hypersensitivity (AHS) as a model to address this question because the disease is linked to memory T cell responses and the HLA risk allele, HLA-B*57:01, and the initiating insult, abacavir, are known.
Research
Quality of benzathine penicillin G: A multinational cross-sectional studyBenzathine penicillin G (BPG) is used as first-line treatment for most forms of syphilis and as secondary prophylaxis against rheumatic heart disease (RHD). Perceptions that poor quality of BPG is linked to reported adverse effects and therapeutic failure may impact syphilis and RHD control programs. Clinical networks and web-based advertising were used to obtain vials of BPG from a wide range of countries.
Research
Association of gestational age and growth measures at birth with infection-related admissions to hospital throughout childhoodChildren who were born with reduced gestational age, birthweight, and birth length have persistently increased rates of infection-related admissions to hospital until age 18 years
Research
Time series analysis of RSV and bronchiolitis seasonality in temperate and tropical Western AustraliaBronchiolitis hospitalisations are a reasonable proxy for the timing of RSV detections, but may not fully capture the magnitude of RSV epidemics
Research
Establishing a process for conducting cross-jurisdictional record linkage in AustraliaWe outline the processes involved in conducting a Proof of Concept data linkage project including the implementation of national data integration principles
Research
Risk factors and comorbidities for invasive pneumococcal disease in Western Australian Aboriginal and non-Aboriginal peopleAustralian Aboriginal people have among the highest rates of invasive pneumococcal disease (IPD) worldwide. This paper investigates clinical diagnosis, risk...
Our team’s vision is to reduce the burden of infectious diseases in children and their families through comprehensive approaches to understanding the burden of disease, developing and optimising diagnosis and treatment strategies and evaluating and informing current and future prevention programs.
Research
The STAMP RSV ProgramSTAMP RSV is a multifaceted program of work with the single focus to prepare the community for the uptake of new and emerging RSV immunisation strategies by providing the evidence to inform public health policy.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.